# **Supporting Information - Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2 - Supporting Information**

Renato Ferreira de Freitas<sup>‡,|,#</sup>, Yanli Liu<sup>‡,||,#</sup>, Magdalena M. Szewczyk<sup>‡</sup>, Naimee Mehta<sup>†</sup>, Fengling Li<sup>‡</sup>, David McLeod<sup>††</sup>, Carlos Zepeda-Velázquez<sup>††</sup>, David Dilworth<sup>‡</sup>, Ronan P. Hanley<sup>†</sup>, Elisa Gibson<sup>‡</sup>, Peter J. Brown<sup>‡</sup>, Rima Al-Awar<sup>††</sup>, Lindsey I. James<sup>†</sup>, Cheryl H. Arrowsmith<sup>‡,&</sup>, Dalia Barsyte-Lovejoy<sup>‡,!</sup>, Jinrong Min<sup>‡,%</sup>, Masoud Vedadi<sup>‡,!</sup>, Matthieu Schapira<sup>‡,!,\*</sup>, Abdellah Allali-Hassani<sup>‡,||,#</sup>,\*

<sup>‡</sup> Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada

<sup>†</sup> Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States

<sup>††</sup> Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada

& Princess Margaret Cancer Centre and Department of Medical Biophysics, University of Toronto, Toronto, ON, M5G 2M9, Canada

<sup>%</sup> Department of Physiology, University of Toronto, Toronto, ON M5S 1A8, Canada

<sup>1</sup>Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada

present address: Centro de Ciências Naturais e Humanas, Universidade Federal do ABC, Rua Arcturus 3, São Bernardo do Campo, SP 09606-070, Brazil.

present address: College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China

present address: Incyte, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA

# equal contributors

\* To whom correspondence should be addressed

p2: Figure S1

p2: Table S2

p3: Characterization of Compound 1

- p3: Figure S2
- p3: Figure S3
- p4: Figure S4
- p5: Figure S5
- p6: Figure S6
- p6: Table S3
- p7: Figure S7
- p7: Figure S8
- p8: Figure S9

p9-13: <sup>1</sup>H NMR Spectra compounds 3c, 3d.

p14-32: Compound purity: analytical spectra



Figure S1. (a) Compound 1 binds NSD2-PWWP1 with a  $K_d$  of 41 ± 8 µM in SPR experiments conducted in triplicate. SPR-sensorgram (upper pane) for the interaction of 1 with NSD2-PWWP1 domain. Multicycle kinetics was used with concentrations from 2 µM to 250 µM (dilution factor of 0.5 was used to yield 8 concentrations). 90 s contact time and 120 s dissociation time at 100 µL/min were used. The steady state values were determined and plotted as a function of the concentration (lower pane). A single binding site model was fitted to the data to calculate  $K_d$ . (b) ITC results showing raw data after integration baseline correction (upper pane) and integrated data and regression (lower pane). n is the number of molecules per binding site,  $K_d$  is the association constant,  $\Delta H$  is the change in enthalpy, and  $\Delta S$  is the change in entropy.

Table S2. Thermal shift in differential static light scattering (DSLS) induced by **1** against seven PWWP domains.

Protein	ΔT <sub>agg</sub> at 400 μM (°C)
BRPF1-PWWP	-0.5
DNMT3b-PWWP	-1.2
MSH6-PWWP	-1.4
NSD2-PWWP1	3.9
NSD3-PWWP1	-0.3
ZMYND11-PWWP	-1.2
ZCWPW1-PWWP	-1.4

### **Characterization of Compound 1**

The original sample was obtained from Enamine (Catalog Number Z1483746373) and assumed to be a racemic mixture. Attempted separation of all 4 diastereoisomers by chiral SFC resulted in only two

peaks in the SFC chromatogram. Peaks showed identical NMR spectra but exhibited equal and opposite optical rotations. These must be enantiomers and thus the original sample must have been made by a diasteroselective route (Figure S2).



Figure S2. Separation of enantiomers from original sample by chiral SFC.

A search of the literature found a paper describing this diastereoselective synthesis from a substituted boronic acid and cyclic amine (Nanda K. K. and Trotter B. W. **Tet. Lett.** (2005) 2025-28). In an effort to determine the activity of the other diasteroisomers, a non-diastereoselective route was developed involving azetidine displacement of an a-bromoester (Figure S3).



Figure S3. Synthesis from (R)-azetidine gave two diastereoisomers. Similar results were obtained starting from (S)-azetidine to give the (S,S) and (S,R) diastereoisomers.

In this case, all four isomers were detected by chiral SFC, however, the diastereoisomers not found in the original material were inactive. The assignment of stereochemistry was based on the diastereoselective product in the original paper which was confirmed by X-ray crystallography (Figure S4).



Figure S4. Chiral preparative SFC separation of diastereoisomers. A) Reaction products from (S)-azetidine gave peaks at 3.1 and 4.9 mins. B) Products from (R)-azetidine gave peaks at 2.6 and 4.1 mins. The original enantiomers correspond to the peaks at 4.1 and 4.9 mins. Lower panels indicate the analytical chiral SFC analysis of collected peaks.

# **Experimental Procedures and Characterization data**

# Separation of commercial material

The commercially available material (30 mg; Enamine Z1483746373) was separated by chiral SFC using an IA column (2 x 25 cm) using 30% MeOH/CO<sub>2</sub> as eluant at a flowrate of 60 mL.min<sup>-1</sup> and 100 bar pressure. Detection by UV at 220 nm. Injection volume was 1.5 mL of 3 mg.mL<sup>-1</sup> in MeOH. Analytical chiral SFC (Fig. 1) used IA column (0.46 x 25 cm) with 40% MeOH/CO<sub>2</sub> as eluant at a flowrate of 3 mL.min<sup>-1</sup> and 100 bar pressure. Detection by UV at 220 nm.

**2R-(2-(4-chlorophenyl)azetidin-1-yl)-2S-(4-cyanophenyl)acetamide** (13 mg).  $[\alpha]_d^{23}$  +35.5° (c=0.205; MeOH). <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  7.81 (d, *J* = 8.2 Hz, 2H), 7.60 (d, *J* = 8.2 Hz, 2H), 7.54 (d, *J* = 8.4 Hz, 2H), 7.36 (d, *J* = 8.4 Hz, 2H), 7.21 (s, 1H), 6.90 (s, 1H), 4.27 (t, *J* = 8.1 Hz, 1H), 4.07 (s, 1H), 3.11 (t, *J* = 6.5 Hz, 1H), 2.73 (dd, *J* = 16.1, 8.0 Hz, 1H), 2.27 (q, *J* = 8.0 Hz, 1H), 1.95 (p, *J* = 9.0 Hz, 1H).

**2S-(2-(4-chlorophenyl)azetidin-1-yl)-2R-(4-cyanophenyl)acetamide** (12 mg).  $[\alpha]_d^{23}$ -29.7° (c=0.337; MeOH). <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  7.81 (d, *J* = 8.2 Hz, 2H), 7.60 (d, *J* = 8.2 Hz, 2H), 7.54 (d, *J* = 8.3 Hz, 2H), 7.36 (d, *J* = 8.3 Hz, 2H), 7.21 (s, 1H), 6.90 (s, 1H), 4.27 (t, *J* = 8.1 Hz, 1H), 4.07 (s, 1H), 3.11 (t, *J* = 6.5 Hz, 1H), 2.73 (dd, *J* = 16.1, 8.0 Hz, 1H), 2.27 (q, *J* = 8.0 Hz, 1H), 1.95 (p, *J* = 9.0 Hz, 1H).



Figure S5: compound **3f** binds wild-type NSD2-PWWP1 but not Y233A or F266A mutants in SPR experiments



Figure S6. Compound 3f binds NSD2-PWWP1 with a  $K_d$  of  $3.42 \pm 0.45 \mu$ M in a SPR experiments conducted in triplicate with 0.5% DMSO concentration. Biotinylated NSD2-PWWP1 domain (208-368) was immobilized on the flow cell of an SA sensor chip in 1x HBS-EP buffer, yielding 5000 RU. The biotinylated RBBP5 (2-538) was immobilized on another flow cell of SA chip, yielding 4300 RU as a negative control. Using the same buffer with 0.5% DMSO and single cycle kinetics with 60 s contact time and a dissociation time of 120s at a flow rate of 75  $\mu$ L/min. The compound was tested at 50  $\mu$ M as the highest concentration and dilution factor of 0.25 was used to yield 5 concentrations.

Table S3.	Crystallog	raphy data	and refinem	ent statistics

	NSD2 + <b>3f</b>	
PDB Code	6UE6	
Data collection		
Space group	$P2_{1}2_{1}2_{1}$	

Cell dimensions	
a, b, c (Å)	69.2.70.3.228.8
$\alpha, \beta, \gamma$ (°)	90.0.90.0.90.0
$\alpha, \beta, \gamma$ ( )	
Resolution (A)	49.33-2.40(2.49-2.40)
(highest resolution	
shell)	
Measured reflections	287140
Unique reflections	44525
R <sub>merge</sub>	8.4(0.997)
I/σI	14.0(1.9)
, Completeness(%)	99.7(97.5)
Redundancy	6.4(5.2)
Refinement	
Resolution (Å)	45.3-2.40
No. reflections (test	44447(2275)
set)	
$R_{\rm work/} R_{\rm free}$ (%)	23.6/25.2
No. atoms	
Protein	7136
Compound	160
B-factors (Å <sup>2</sup> )	
Protein	61.4
Compound	47.5
RMSD	
Bond lengths (Å)	0.010
Bond angles (º)	0.99
Ramachandran plot %	
residues	
Favored	99.5
Additional allowed	0.5
Generously allowed	0
Disallowed	0



Figure S7: One sigma electron density unambiguously defines the ligand binding pose



Ligand interaction VdW Energy compound 3f (cyclopropyl) : -27.5 kcal/mol Compound 3c (isopropyl): 1.1 kcal/mol

Figure S8. A computational model indicates steric clashes with the isopropyl of compound **3c**. The cyclopropyl of **3f** was replaced with an isopropyl in ICM (Molsoft, San Diego). The isopropyl methyl groups are more distant resulting in increased bulk (the isopropyl geometry is absolutely similar to the one found in ligand bk1, PDB code 3I7B). The energy of the modified flexible ligand was locally minimized in the internal coordinate space, while conserved atoms were tethered to their original position (with a tether weight tzWeight=200). The Van der Waals energy of the bound ligand was calculated in ICM (force-field: protein: ECEPP/3, ligand: mmff).



Figure S9. (a) Comparison between the apo (PBD ID: 5VC8, magenta) and bound (green) conformation of the NSD2-PWWP1. The loop residues G268, D269, A270, and P271 connecting the  $\beta$ 3 and  $\beta$ 4 strands

display different conformations in the two structures. (b) In the apo structure the residues E272 and Y233 are closing the pocket. (c) When the ligand binds these residues move away opening the pocket.

# N-isopropyl-4-fluorobenzylamine



min

### Compound 3c





#### **Compound 3d**







# Compound purity: analytical spectra





























# Compound 3c









